Amar Bukhari, MD
Pulmonary Disease · New Brunswick, NJNPI 1518917822
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,125 of the $20,954 with a category attached, or 67.4%. Teleflex LLC accounts for 73.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $9,971 and has fallen 64.9% since, to $3,501 in 2025. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $183.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$15K
- Intuitive Surgical$3K
- AstraZeneca$541
- Sanofi$407
- GSK$181
- Harmony Biosciences LLC$169
- plus $1K from 19 others
Across 5 payments — averaging $2930.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$15K
What the payments were for
- Consulting fees$14,12567%
- Travel & lodging$3,90519%
- Food & beverage$2,77013%
- Education$1541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 18 | $15,353 |
| Intuitive Surgical | 19 | $3,231 |
| AstraZeneca | 14 | $541 |
| Sanofi | 14 | $407 |
| GSK | 11 | $181 |
| Harmony Biosciences LLC | 4 | $169 |
| Boehringer Ingelheim | 4 | $163 |
| Sanofi-aventis U.S. LLC | 2 | $154 |
| Covidien LP | 1 | $137 |
| Philips North America LLC | 5 | $110 |
| Penumbra, Inc. | 1 | $108 |
| Inspire Medical Systems, Inc. | 3 | $71 |
| Pulmonx Corporation | 1 | $43 |
| La Jolla Pharmaceutical Company | 2 | $39 |
| Boston Scientific | 2 | $37 |
| Insmed, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Merck | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Verona Pharma, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Resmed Corp | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arrow$14,306
- Da Vinci Surgical System$2,934
- TEZSPIRE$377
- superDimension$137
- Wakix$120
- DUPIXENT$120
- Indigo System$108
How this compares
$20,954 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $170,034 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $97,411 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $42,881 |
| Spiriva RespimatTiotropium Bromide | 42 | $39,781 |
| Arnuity ElliptaFluticasone Furoate | 62 | $27,804 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $17,137 |
| Qvar RedihalerBeclomethasone Dipropionate | 28 | $12,370 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $12,035 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,765 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,584 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $6,683 |
| Pulmicort FlexhalerBudesonide | 11 | $5,927 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $4,675 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,616 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $163 | $209,81555 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta, Anoro Ellipta | $181 | $189,896242 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $541 | $14,51028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in New Brunswick
- Reynold PanettieriNew Brunswick$1M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.